WHAT IS CLAIMED IS:

1. Use of ~~an anti-VEGF antibody~~bevacizumab in the manufacture of a medicament for treating a patient diagnosed with stage III or IV ovarian cancer, wherein the bevacizumab is to be administered every three weeks at 15mg/kg for five cycles , starting at cycle 2, and carboplatin at a dose of an area under the curve of 6 and paclitaxel at a dose of 175 mg/m^2 are to be administered every three weeks for six cycles, starting on cycle 1; wherein a maintenance dose of said bevacizumab at 15 mg/kg every three weeks is to be administered for cycles 7 through 22; ~~the medicament is to be administered in a treatment regimen with a chemotherapy that is to be followed by anti-VEGF maintenance therapy, wherein the chemotherapy of the treatment regimen comprises administration of at least one chemotherapeutic agent,~~ and wherein the treatment regimen effectively extends the progression free survival of the patient.

~~2. The use of claim 1, wherein the chemotherapeutic agent is taxane, paclitaxel, docetaxel, paclitaxel protein-bound particles (e.g., Abraxane®), platinum analogue, carboplatin, gemcitabine, or combinations thereof.~~

~~3. The use of claim 1, wherein the chemotherapy of the treatment regimen comprises an administration selected from the group consisting of: (a) administration of taxane and carboplatin, (b) administration of carboplatin and gemcitabine, and~~
~~(c) administration of paclitaxel and carboplatin.~~

42. The use of claim 1, wherein the patient is selected from the group consisting of: (a) a patient diagnosed with previously untreated ovarian cancer, and
(b) a patient diagnosed with recurrent ovarian cancer.

~~5. The use of claim 1, wherein said anti-VEGF antibody is selected from the group consisting of: (a) an anti-VEGF antibody that binds the same epitope as the monoclonal anti-VEGF antibody A4.6.1 produced by hybridoma ATCC HB-10709, and~~
~~(b) a humanized antibody.~~

~~6. The use of claim 5 part (b), wherein the anti-VEGF antibody is selected from the group consisting of: (a) a humanized A4.6.1 antibody or fragment thereof,~~

~~(b) bevacizumab, and~~

~~(c) an anti-VEGF antibody that has a heavy chain variable region comprising the following amino acid sequence:~~

~~EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP HYYGSSHWYF DVWGQGTLVT VSS (SEQ ID NO.1)~~

~~and a light chain variable region comprising the following amino acid sequence:~~

~~DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKR (SEQ ID NO.2).~~

~~7. The use of claim 1, wherein the anti-VEGF antibody is bevacizumab and the chemotherapy of the treatment regimen comprises administration of capecitabine and paclitaxel or docetaxel.~~

~~8. The use of claim 1, wherein the anti-VEGF antibody is bevacizumab and the chemotherapy of the treatment regimen comprises administration of carboplatin and gemcitabine.~~

~~93~~. The use of claim 1, wherein the progression free survival of the patient is selected from the group consisting of: (a) a progression free survival extended by at least about 3.8 month or more when compared to another patient not treated with the ~~anti-VEGF~~bevacizumab maintenance therapy, and (b) a progression free survival extended by at least about 2.3 months or more compared to another patient not treated with ~~anti-VEGF antibody~~bevacizumab.

~~10. The use of claim 2, wherein the paclitaxel is to be administered as in a Figure selected from the group consisting of: (a) Figure 1, (b) Figure 2, and (c) Figure 8.~~

~~11. The use of claim 2, wherein the carboplatin is to be administered as in a Figure selected from the group consisting of: (a) Figure 1, (b) Figure 2, (c) Figure 11, and (d) Figure 8.~~

~~12. The use of claim 2, wherein the docetaxel is to be administered as in Figure 1.~~

~~13. The use of claim 2, wherein the gemcitabine is to be administered as in Figure 11.~~

~~14. The use of claim 2, wherein the anti-VEGF is to be administered as in an arm selected from the group consisting of: (a) arm III of Figure 1, (b) arm III of Figure 2, (c) arm II of Example 3, and (d) Arm B of Figure 8.~~

~~15. A kit for treating previously untreated ovarian cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with taxane therapy and carboplatin followed by anti-VEGF maintenance therapy, wherein the instructions recite that the progression free survival for patients receiving taxane therapy and carboplatin therapy and bevacizumab is 14.1 months with a hazard ratio of 0.717 (p-value <0.0001).~~

~~16. The kit of claim 15, wherein the anti-VEGF antibody is selected from the group consisting of: (a) an anti-VEGF antibody that has a heavy chain variable region comprising the following amino acid sequence:~~

~~EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW~~

~~INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP~~

~~HYYGSSHWYF DVWGQGTLVT VSS (SEQ ID No. 1)~~

~~and a light chain variable region comprising the following amino acid sequence:~~

~~DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF~~

~~TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ~~

~~GTKVEIKR (SEQ ID No. 2), and~~

~~(b) bevacizumab.~~

~~17. The kit of claim 15, wherein the patient has stage III or IV ovarian cancer.~~

~~18. A method of instructing a human subject with ovarian cancer, the method comprising providing instructions to receive ovarian cancer treatment with an anti-VEGF antibody concurrent with chemotherapy followed by anti-VEGF maintenance therapy so as to increase progression free survival of the subject.~~

~~19. The method of claim 18, wherein the instructions further comprise providing instructions to receive treatment with at least two chemotherapeutic agent.~~

~~20~~4. A promotional method, comprising promoting administration of an anti-VEGF antibody, wherein the anti-VEGF antibody is bevacizumab; wherein the bevacizumab is to be administered every three weeks at 15mg/kg for five cycles , starting at cycle 2, and carboplatin at a dose of an area under the curve of 6 and paclitaxel at a dose of 175 mg/m^2 are to be administered every three weeks for six cycles, starting on cycle 1; wherein a maintenance dose of said bevacizumab at 15 mg/kg every three weeks is to be administered for cycles 7 through 22; ~~concurrent with chemotherapy followed by anti-VEGF maintenance therapy~~ for treatment of stage III or IV ovarian cancer in a human subject so as to increase progression free survival of the subject.

~~21. The method of claim 20, wherein the method further comprises promoting the administration of at least two chemotherapeutic agents.~~

~~22~~5. The method of claim ~~20~~4, wherein the promotion is selected from the group consisting of:

(a) a promotion by a package insert, wherein the package insert provides instructions to receive cancer treatment with ~~an anti-VEGF antibody~~bevacizumab,

(b) a promotion by a package insert accompanying a commercial formulation of ~~the anti-VEGF antibody~~bevacizumab,

(c) a promotion by a package insert accompanying a commercial formulation of the ~~chemotherapeutic agents~~paclitaxel and carboplatin,

(d) a promotion by written communication to a physician or health care provider, and

(e) a promotion by oral communication to a physician or health care provider.

~~23~~6. The method of claim ~~20~~4, wherein the promotion is to be followed by the treatment of the subject with the bevacizumab, ~~anti-VEGF antibody, and the chemotherapeutic agents~~paclitaxel and carboplatin, followed by bevacizumab ~~anti-VEGF~~ maintenance therapy.

~~24~~7. A business method, comprising marketing an anti-VEGF antibody therapy concurrent with chemotherapy followed by anti-VEGF maintenance therapy for treatment of stage III or IV ovarian cancer in a human subject so as to increase progression free survival of the subject, wherein the anti-VEGF antibody is bevacizumab; wherein the bevacizumab is to be administered every three weeks at 15mg/kg for five cycles , starting at cycle 2, and carboplatin at a dose of an area under the curve of 6 and paclitaxel at a dose of 175 mg/m^2 are to be administered every three weeks for six cycles, starting on cycle 1; wherein a maintenance dose of said bevacizumab at 15 mg/kg every three weeks is to be administered for cycles 7 through 22.

~~25~~8. The method of claim ~~24~~7, wherein the marketing is to be followed by treatment of the subject with the ~~anti-VEGF antibody~~bevacizumab concurrent with chemotherapy followed by ~~anti-VEGF~~ bevacizumab maintenance therapy.

~~26. The method of any one of claims 18, 20 or 24, wherein the chemotherapeutic agent is taxane, paclitaxel, docetaxel, paclitaxel protein-bound particles (e.g., Abraxane®), platinum analogue, carboplatin, gemcitabine, or combinations thereof.~~

~~27. The method of any one of claims 18, 20 or 26, wherein the anti-VEGF antibody is bevacizumab.~~

~~28. The use of claim 1, wherein the anti-VEGF antibody is bevacizumab and the chemotherapy of the treatment regimen comprises administration of paclitaxel and carboplatin.~~

~~299~~. A kit for treating previously untreated stage III or IV ovarian cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with paclitaxel and carboplatin followed by anti-VEGF maintenance therapy, wherein the instructions recite that the progression free survival for patients receiving paclitaxel, carboplatin and anti-VEGF antibody is 18.3 months with a hazard ratio of 0.79; wherein the anti-VEGF antibody is bevacizumab; wherein the bevacizumab is to be administered every three weeks at 15mg/kg for five cycles , starting at cycle 2, and carboplatin at a dose of an area under the curve of 6 and paclitaxel at a dose of 175 mg/m^2 are to be administered every three weeks for six cycles, starting on cycle 1; wherein a maintenance dose of said bevacizumab at 15 mg/kg every three weeks is to be administered for cycles 7 through 22.